5 November 2021 - The Outcome Statement from the October 2021 Drug Utilisation SubCommittee meeting is now available.

The Drug Utilisation Sub-Committee of the PBAC held its 103rd meeting on the 30 September – 1 October 2021.

DUSC reviewed the utilisation of the following PBS medicines in October 2021:

• Golimumab for the treatment of non-radiographic axial spondyloarthritis
• Nivolumab in combination with ipilimumab for first-line Stage IV clear cell variant renal cell carcinoma
• Pembrolizumab for locally advanced or metastatic urothelial carcinoma
• Bictegravir with emtricitabine and tenofovir alafenamide and dolutegravir and rilpivirine for HIV and PrEP
• Tolvaptan for autosomal dominant polycystic kidney disease

Read DUSC outcome statement